DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: Placebo matching BI 3804379
Drug: BI 3804379

First Posted Date: 2024-08-28

Last Posted Date: 2025-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 106

Registration Number: NCT06575400

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body

Phase 1

Suspended

Conditions: Healthy

Interventions: Drug: BI 1839100 (C-14) formulation 1
Drug: BI 1839100
Drug: BI 1839100 (C-14) formulation 2

First Posted Date: 2024-08-26

Last Posted Date: 2025-02-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT06572111

Locations: 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Phase 1

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: Survodutide
Drug: Bupropion
Drug: Caffeine
Drug: Midazolam

First Posted Date: 2024-08-21

Last Posted Date: 2025-04-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT06564441

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test Different Doses of BI 1569912 in People With Depression

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Placebo matching BI 1569912
Drug: BI 1569912

First Posted Date: 2024-08-16

Last Posted Date: 2025-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 224

Registration Number: NCT06558344

Locations: 🇺🇸
Surburban Research Associates, Inc., Media, Pennsylvania, United States
🇺🇸
Clinical Innovations, Inc, Bellflower, California, United States
🇺🇸
ASCLEPES Research Centers, P.C. dba Alliance Research, Long Beach, California, United States

and more 38 locations

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Phase 3

Recruiting

Conditions: Kidney Disease, Chronic

Interventions: Drug: Placebo matching BI 690517
Drug: BI 690517
Drug: Empagliflozin

First Posted Date: 2024-08-01

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 11000

Registration Number: NCT06531824

Locations: 🇺🇸
Apogee Clinical Research, Huntsville, Alabama, United States
🇺🇸
Southwest Kidney Institute, Surprise, Arizona, United States
🇺🇸
Total Research Group, LLC, Miami, Florida, United States

and more 108 locations

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: BI 765883
Drug: gemcitabine
Drug: nab-paclitaxel

First Posted Date: 2024-07-30

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT06528093

Locations: 🇺🇸
HealthONE, Denver, Colorado, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States

and more 15 locations

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Recruiting

Conditions: Kidney Disease, Chronic

Interventions: Drug: JARDIANCE®

First Posted Date: 2024-07-30

Last Posted Date: 2024-11-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1000

Registration Number: NCT06527846

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

A Study in Healthy Men to Test How BI 1569912 is Processed in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1569912 (C-14)
Drug: BI 1569912 (C-13)

First Posted Date: 2024-07-25

Last Posted Date: 2024-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT06520553

Locations: 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands

A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Spesolimab

First Posted Date: 2024-07-25

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT06520514

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)

Phase 1

Recruiting

Conditions: Cystic Fibrosis

Interventions: Genetic: BI 3720931
Drug: Placebo
Device: Inhaler

First Posted Date: 2024-07-23

Last Posted Date: 2025-04-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT06515002

Locations: 🇫🇷
HOP Gui de Chauliac, Montpellier, France
🇬🇧
University Hospital Llandough, Cardiff, United Kingdom
🇬🇧
Queen Elizabeth University Hospital, Glasgow, United Kingdom

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy